Change propels new ways of thinking, operating, and innovating. Change Is the Cure, BeiGene’s ESG strategy, frames our approach for helping change the world for the better. It begins with our commitment to advancing global health by making innovative medicines more accessible to more people around the world.
John V. Oyler, Co-Founder, Chairman, and CEO
Change Is the Cure outlines our five ESG focus areas and strategic priorities, and we have committed to ambitious long-term goals in each of these areas. These goals are also intentionally aligned with the UN SDGs, specifically three SDGs.